Tg(TcraC14,TcrbC14)DUC18Pmal
Transgene Detail
|
|
| Symbol: |
Tg(TcraC14,TcrbC14)DUC18Pmal |
| Name: |
transgene insertion DUC18, Paul M Allen |
| MGI ID: |
MGI:6304989 |
| Synonyms: |
DUC18 |
| Transgene: |
Tg(TcraC14,TcrbC14)DUC18Pmal Location: unknown
|
| Alliance: |
Tg(TcraC14,TcrbC14)DUC18Pmal page
|
|
|
|
| Transgene Type: |
|
Transgenic (Inserted expressed sequence) |
| Mutation: |
|
Insertion
|
| |
|
Mutation details: Valpha10.1 V-J and Vbeta8.3 V-D-J segments were amplified by RT-PCR from the C18 T cell clone. The V-J and V-D-J exon cassettes were cloned into TCR and shuttle vectors, and founder mice were screened by PCR for cointegration of the alpha and beta minigene constructs and by FACS for transgenic TCR expression. One founder was identified. These mice express an H-2Kd -restricted transgenic T cell receptor specific for the syngeneic CMS5 fibrosarcoma rejection antigen mutated ERK2(136-144).
(J:271337)
|
|
|
| Mouse strains and cell lines
available from the International Mouse Strain Resource
(IMSR) |
| Carrying this Mutation: |
Mouse Strains: 0 strains available
Cell Lines: 0 lines available
|
|
| Original: |
J:271337 Hanson HL, et al., Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity. 2000 Aug;13(2):265-76 |
| All: |
18 reference(s) |
|
Analysis Tools
